Abbisko Cayman Sets 2026 AGM to Approve Results, Board Changes and 20% Share Issue Mandate

Abbisko Cayman Limited ( (HK:2256) ) has issued an update.

Abbisko Cayman Limited has convened its annual general meeting for May 20, 2026 in Shanghai, where shareholders will review and approve the audited consolidated financial statements for the year ended December 31, 2025, along with the reports of the board and external auditor. The meeting will also consider the re-election of two independent non-executive directors, authorize the board to set directors’ and auditor’s remuneration, re-appoint Ernst & Young as auditor, and grant directors a refreshed share issuance mandate of up to 20% of the company’s existing share capital, underscoring ongoing capital management flexibility and board continuity.

The proposed general mandate to allot and issue up to 20% of the company’s share capital, excluding treasury shares, is designed to give the board additional flexibility to raise equity or execute corporate actions without convening separate shareholder meetings. If approved, these resolutions would maintain the company’s governance stability, preserve its access to capital markets, and signal continuity in oversight and financial reporting practices to investors and other stakeholders.

The most recent analyst rating on (HK:2256) stock is a Buy with a HK$27.10 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

More about Abbisko Cayman Limited

Abbisko Cayman Limited, listed in Hong Kong, operates in the biopharmaceutical sector and is incorporated in the Cayman Islands with limited liability. The company is governed by a board of directors and audited by Ernst & Young, reflecting a conventional corporate and regulatory structure for a HKEX-listed issuer.

Average Trading Volume: 1,874,686

Technical Sentiment Signal: Buy

Current Market Cap: HK$9.25B

See more data about 2256 stock on TipRanks’ Stock Analysis page.